Home Companies Catalysts Deep Dives
Vectibix panitumumab APPROVED
Drug Profile
ModalityMonoclonal antibody
RouteIV
Therapy AreaOncology
Launch2006-09-27
Peak Sales Est$1200M
Formulations[{"id":"vectibix-iv","doses":"6 mg/kg","route":"IV","device":"IV infusion","setting":"OUTPATIENT_INF
Companies
AMGN (ORIGINATOR)100%
Mechanism: EGFR inhibitor (monoclonal antibody)
Expert: Fully human IgG2 monoclonal antibody targeting EGFR. Inhibits ligand binding and downstream RAS/MAPK signaling.
Everyday: Blocks the EGFR receptor on cancer cells, preventing them from receiving growth signals.
Targets: ["EGFR"]
Revenue History
PeriodRevenue ($M)
2024$1,045M
2025$1,175M
Programs (1)
IndicationStageKey StudyRegional Status
WT RAS mCRCAPPROVEDPRIME / 20050203[{"stage":"APPROVED","region":"US","approval_date":"2006-09-27"},{"stage":"APPRO
Data from Supabase · Updated 2026-03-24